Clinical Trial

Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma

Study acronym: GALAXY-02
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 9, 2024 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Previous trials, such as ADURA and CTONG, have demonstrated the benefits of neoadjuvant targeted therapy in patient with EGFR mutations , which can effectively reduce the extent of tumors and improve the survival outcomes. However, clinical trials of neoadjuvant targeted therapy in NSCLC have rarely enrolled patients with EGFR-mutated lung squamous cell carcinoma due to its rarity, which means that the safety and feasibility of neoadjuvant osimertinib in patients with resectable stage II-IIIB EGFR-mutated lung squamous cell carcinoma remains controversial.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-22.
Trial Details
NCT Number NCT06383728
Lead Sponsor The First Affiliated Hospital of Guangzhou Medical University
Conditions Lung Cancer, Carcinoma, Squamous Cell
Enrollment 51 participants
Start Date 2024-04-01
Primary Completion 2025-10-31 (estimated)
Study Completion 2029-04-30 (estimated)
Updated on ClinicalTrials.gov 2024-05-09